Longenesis enters the Singapore market as a participant of 500 Startups Singapore program to accelerate healthcare research in the region
Longenesis was selected to participate in the first-ever 500 Startups Global Launch in Singapore, bringing its technology to accelerate medical research in Singapore.
SINGAPORE, March 12, 2020
Longenesis joins the 500 Startups family in a 16-week Singapore-based program designed to accelerate the growth of the best-selected startups through deep market insights, hands-on coaching and exposure to 500’s network of partners, experts, and talent.
For the next 4 months, our team will be fully immersed in the Singapore market leveraging the 500 Startups’ network to multiply the number of strategic partnerships and accelerate international exposure of the company.
Healthcare research, being accelerated by the integration of technologies, faces a variety of challenges, including data privacy, process transparency, and ethical aspects. Seeing transparency as a cornerstone value in the future of life data exchange processes, in Q2 2019 Longenesis, in collaboration with Bitfury, has announced the launch of Dynamic Consent Management Toolkit (Longenesis Themis) solving the legal challenge of legitimate biomedical data utilization for clinical studies, allowing patients to be proactively involved in the clinical and research projects and providing transparency and auditability mechanisms, putting patients as a centric stakeholder of such process [1]. The tool is also tailored to comply with the Singapore Personal Data Protection Act and applicable to APAC region regulations.
Inbound with the central product, Longenesis Proteus, company allows any clinical and/or research institution, patients association, biobank, and MedTech company to join the network and get connected with Clinical Research organizations and Pharma companies for proactive patient involvement.
Apart from its work connecting healthcare stakeholders and pharmaceutical industry, Longenesis has so far already conducted studies on Breast Cancer multi-modal risk calculation, Diabetes patients’ medical treatment monitoring and pharmacovigilance, being well-equipped to address patient needs in the APAC region [2].
References:
[1]: Bitfury and Longenesis Launch Medical Consent Solution, The Bitfury Group, April 4, 2019. Available: https://medium.com/meetbitfury/bitfury-and-longenesis-launch-medical-consent-solution-457bdf51fc9
[2]: Longenesis joins forces with Northern European oncologists, Labs of Latvia, January 22, 2020. Available: https://labsoflatvia.com/en/news/longenesis-joins-forces-with-northern-european-oncologists
Longenesis Media contact:
info@longenesis.com
+37126354885
About 500 Startups
500 Startups is a venture capital firm on a mission to discover and back the world’s most talented entrepreneurs, help them create successful companies at scale, and build thriving global ecosystems. It is one of the most active venture capital firms in the world.
Since its inception in Silicon Valley, 500 Startups has invested in over 2,400 companies via its 5 global funds and 17 thematic funds dedicated to either specific geographic markets or verticals. Its 100+ team members are located in 20 countries around the world in order to support the 500 Startups global portfolio of investments which spans more than 75 countries.
About Longenesis
Longenesis is a partnership between Insilico Medicine, a leading artificial intelligence company that uses deep learning for drug discovery, and the Bitfury Group, the leading full-service blockchain technology company. Longenesis is the exclusive healthcare application provider for open-source framework Exonum™. The main goal of the company is to disrupt an industry for compliant access to medical data for clinical studies with a set of technological tools developed for pharma, clinics, researchers, data analytics companies, and patients’ proactive involvement in clinical and research studies, generating prospective biomedical data for insights generation.
